May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Tractional Retinal Detachment In Severe Diabetic Retinopathy After The Injection Of Bevacizumab (avastin®)
Author Affiliations & Notes
  • S. S. Couvillion
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • P. J. Rosenfeld
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • H. W. Flynn, Jr.
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships S.S. Couvillion, None; P.J. Rosenfeld, Genentech, F; Eyetech, F; Alcon Laboratories, F; Genentech, C; Eyetech Pharmaceuticals, C; Novartis, C; Allergan, C; Protein Design Labs, C; Tanox, C; Genaera, C; Jerini AG, C; Quark Inc, C; Athenagen, C; Genentech, R; Eyetech, R; Novartis Ophthalmics, R; Zeiss Meditec, R; H.W. Flynn, Genentech, F; Eyetech, F; Alcon Laboratories, F; Novartis Ophthalmics, F; Pfizer, F.
  • Footnotes
    Support Supported by NIH center grant P30 EY014801 and by an unrestricted grant to the University of Miami from Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5773. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. S. Couvillion, P. J. Rosenfeld, H. W. Flynn, Jr.; Tractional Retinal Detachment In Severe Diabetic Retinopathy After The Injection Of Bevacizumab (avastin®). Invest. Ophthalmol. Vis. Sci. 2007;48(13):5773.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: The use of intravitreal bevacizumab (Avastin®) in the setting of diabetic retinopathy has been described as a surgical adjuvant and as an important clinical tool. The current study describes the onset of tractional retinal detachment after the injection of bevacizumab in the setting of severe proliferative diabetic retinopathy in patients with poorly controlled blood glucose

Methods:: This is a non-comparative, consecutive case series involving 5 patients. Intravitreal injections of 1.25 mg of bevacizumab were administered in patients with severe fibrovascular proliferation with and without tractional detachment. All patients had documentary fundus photography before and after intravitreal injection.

Results:: The study consisted of 5 eyes of 5 patients. The mean age was 35. 3 of the 5 patients had no prior laser or received concomitant pan retinal photocoagulation. All 5 patients went on to develop new tractional retinal detachments over the following 2 months with a mean time to presentation of 49 days. Patients lost an average of 4 lines of vision.

Conclusions:: Promising results have been reported with the use of bevacizumab in the setting of advanced diabetic retinopathy. However, in the setting of severe fibrovascular proliferation, intravitreal Avastin can be considered a temporizing measure to reduce vasculature prior to definitive therapy such as panretinal photocoagulation or pars plana vitrectomy. There is a risk of tractional retinal detachment in eyes with severe fibrovascular proliferation or prexisiting tractional detachment with the use of bevacizumab.

Keywords: diabetic retinopathy • drug toxicity/drug effects • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×